Advertisement

Topics

NantKwest Company Profile

00:49 EST 14th December 2018 | BioPortfolio

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.


News Articles [16 Associated News Articles listed on BioPortfolio]

NantKwest gets rights to Viracta's Phase II-ready HDAC inhibitor

Viracta Therapeutics Inc. granted NantKwest Inc. exclusive rights to use its Phase II-ready HDAC inhibitor VRx3996 in combination with NantKwest's natural killer (NK) cell therapies for cancer and inf...

Viracta raises $18.4mm in Series B round

Viracta Therapeutics Inc. (therapies for virus-based cancers) closed the first tranche of its $18.4mm Series B round. NantKwest led and was joined by new investor Wicklow Capital and returning backers...

NantKwest Gets A Shot In The Arm, CPRX Awaits FDA Word, FOMX Meets Phase 3 Goals

Today's Daily Dose brings you news about the near-term catalysts of Catalyst Pharma; progress in Entasis' gonorrhea study; positive results of Foamix Pharma's phase III papulopustular rosacea studies;...

Management tracks: Sanofi, NantKwest

NantKwest to Present at 2018 Cantor Global Healthcare Conference

NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global ...

NantKwest Turning Heads, AUTL To Report Data In Dec., PTLA Marches Ahead

The following are some of today's top gainers in the pharma/biotech sector.

NantKwest to Present at Jefferies 2018 Global Healthcare Conference

NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong, Chairman & CEO of NantKwest, wil...

NantKwest Names Sonja Nelson Chief Financial Officer

NantKwest, Inc. (Nasdaq: NK) today announced the elevation of Sonja Nelson, chief accounting officer for the company, to the role of Chief Financial Officer (CFO). This pres...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

NantKwest

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) ...

NantKwest, Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) ...

NantKwest Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) ...

More Information about "NantKwest" on BioPortfolio

We have published hundreds of NantKwest news stories on BioPortfolio along with dozens of NantKwest Clinical Trials and PubMed Articles about NantKwest for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NantKwest Companies in our database. You can also find out about relevant NantKwest Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record